"I think that most innovation focuses on adjacencies and is viewed to be continuous innovation, which means that what you're working on is an iteration over what's been worked on before. And once in a while, you have discontinuous innovation where it's not easy to connect what's being proposed with what was done before. And that's much harder or much less predictable, but often is categorized as a breakthrough because people neither expected it, nor could they in the beginning assess its value."
"He thinks deeply about how man and machine can work together to solve some of the world's largest problems, whether they're in the world of science, business, or society. Now, we've spoken to him on IdeaCast before, back in 2021, to talk specifically about leadership and innovation lessons learned in the development of Moderna's COVID vaccine, but things move fast in today's business world, and his thinking has evolved accordingly."
Most innovation focuses on adjacencies and is continuous, meaning efforts iterate on previous work. Occasionally innovation is discontinuous, making it difficult to connect proposals with prior practice; such discontinuous change is harder, less predictable, and often labeled a breakthrough because people neither expected it nor could initially assess its value. Breakthrough innovation is relevant across industries. The capacity to predict breakthroughs or to follow a process to create them remains an open challenge. Noubar Afeyan is founder and CEO of Flagship Pioneering and co‑founder and chair of Moderna. He is a biochemical engineer and entrepreneur who has helped spawn more than 100 life‑science and technology startups.
Read at Harvard Business Review
Unable to calculate read time
Collection
[
|
...
]